PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
暂无分享,去创建一个
D. Douek | S. Rosenberg | S. Darko | J. Yang | S. Turcotte | A. Mixon | P. Robbins | E. Tran | M. Dudley | J. Wunderlich | A. Gros | J. Almeida | K. Hanada | Yong F Li | X. Yao | Shawn Farid | S. Farid
[1] Y. Lee. TCR Repertoire Analysis , 2016 .
[2] P. Robinson,et al. TCR Repertoire Analysis by Next Generation Sequencing Allows Complex Differential Diagnosis of T Cell–Related Pathology , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] G. Coukos,et al. CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor , 2013, Clinical Cancer Research.
[4] S. Rosenberg,et al. Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy , 2013, The Journal of Immunology.
[5] Todd M. Allen,et al. Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells , 2013, The Journal of Immunology.
[6] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[7] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[8] Seth M Steinberg,et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Legat,et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion , 2013, Nature Immunology.
[10] Jimmy Lin,et al. Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.
[11] Nathalie Vigneron,et al. Database of T cell-defined human tumor antigens: the 2013 update. , 2013, Cancer immunity.
[12] S. Rosenberg,et al. Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma , 2012, Clinical Cancer Research.
[13] T. Schumacher,et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients , 2012, Oncoimmunology.
[14] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[15] M. Ostrowski,et al. Antigen-Independent Induction of Tim-3 Expression on Human T Cells by the Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Is Associated with Proliferation and Is Dependent on the Phosphoinositide 3-Kinase Pathway , 2012, The Journal of Immunology.
[16] Ornella Pagliano,et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. , 2012, Cancer research.
[17] J. Delrow,et al. Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State , 2012, Science.
[18] H. Pircher,et al. Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization , 2012, PloS one.
[19] T. Eberlein. Durable Complete Responses in Heavily Pretreated Patients with metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2012 .
[20] R. Ahmed,et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. , 2011, Immunity.
[21] T. Schumacher,et al. High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations , 2011, PloS one.
[22] Pedro Romero,et al. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. , 2011, The Journal of clinical investigation.
[23] E John Wherry,et al. T cell exhaustion , 2011 .
[24] S. Henson,et al. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? , 2011, Nature Reviews Immunology.
[25] A. Trautmann,et al. Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors , 2011, PloS one.
[26] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Rosenberg,et al. Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells , 2010, Journal of immunotherapy.
[28] P. Ascierto,et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. , 2010, Seminars in oncology.
[29] Jenna M. Sullivan,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.
[30] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[31] G. Freeman,et al. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity , 2010, Immunological reviews.
[32] S. Rosenberg,et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.
[33] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[34] T. Watts,et al. Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges , 2009, Immunological reviews.
[35] M. Croft. The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.
[36] Antonio Polley,et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.
[37] V. Appay,et al. Phenotype and function of human T lymphocyte subsets: Consensus and issues , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[38] V. Sondak,et al. CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues , 2008, Annals of Surgical Oncology.
[39] J. M. van der Hulst,et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction element , 2008, International journal of cancer.
[40] E. Wherry,et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.
[41] G. Freeman,et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status , 2007, AIDS.
[42] E. Rosenberg,et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction , 2007, Nature Immunology.
[43] P. Greenberg,et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. , 2007, Blood.
[44] B. Palmer,et al. Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells Associated with Reversible Immune Dysfunction , 2007, Journal of Virology.
[45] R. Balderas,et al. Corrigendum: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.
[46] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[47] Philip J. R. Goulder,et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.
[48] R. Balderas,et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.
[49] S. Migueles,et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses , 2005, The Journal of experimental medicine.
[50] A. Lanfranco,et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.
[51] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] S. Rosenberg,et al. Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .
[53] S. Rosenberg,et al. T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product , 2004, The Journal of Immunology.
[54] A. Mackensen,et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. , 2004, Cancer research.
[55] Jonathan W. Yewdell,et al. Immune recognition of a human renal cancer antigen through post-translational protein splicing , 2004, Nature.
[56] Sujung Park,et al. 4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11 , 2002, The Journal of Immunology.
[57] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[58] B. Seliger,et al. Longitudinal analysis of the T‐cell receptor (TCR)‐VA and ‐VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen , 2002, Clinical and experimental immunology.
[59] D. Busch,et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer , 2002, Nature Medicine.
[60] T. Okazaki,et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.
[61] T. Blankenstein,et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay , 2001, Nature Medicine.
[62] T. Honjo,et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.
[63] J. Altman,et al. Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.
[64] B. Kwon,et al. Role of 4-1BB in immune responses. , 1998, Seminars in immunology.
[65] T. Honjo,et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.
[66] J. Boss,et al. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. , 1996, Journal of immunology.
[67] E. Appella,et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.
[68] S. Steinberg,et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] R. Henderson,et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.
[70] T. Honjo,et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.
[71] R. Freedman,et al. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. , 1991, Journal of immunology.
[72] T. Waldmann. The multi-subunit interleukin-2 receptor. , 1989, Annual review of biochemistry.